Back to search
FDAFDA · Food and drugs·Recall number D-0527-2026

Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.

Published May 20, 2026 · Recall initiated: March 13, 2026

Summary

FDA records drug Class II recall D-0527-2026, published May 20, 2026 and initiated March 13, 2026. Recalling firm: ENDO USA, Inc.; Status: Ongoing; Reported quantity: 34,293 vials; Lot: Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Crystallization; identified as Buprenorphine free base

What to do

Voluntary: Firm initiated · Letter

Get an email if BUPRENORPHINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUPRENORPHINE HYDROCHLORIDE
Manufacturer
ENDO USA, Inc.
Distributor
USA Nationwide
Lot
Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05. recalled?

Yes. FDA published recall D-0527-2026 on May 20, 2026. Reported hazard: Crystallization; identified as Buprenorphine free base

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUPRENORPHINE HYDROCHLORIDE.